pfizer_istock-458618835_no_limit_pictures--2

no_limit_pictures / iStockphoto.com

14 August 2018Americas

Medtech company backs down from Pfizer TM oppositions

Medical technology company Biocompatibles UK last week withdrew its oppositions to two trademarks applied for by Pfizer, four months after settlement negotiations.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

The doctrine of equivalents in the medtech arena

18 November 2020 The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.

TM oppositions against Pfizer suspended amid negotiations

19 April 2018 Two trademark oppositions against Pfizer have been suspended as the parties are engaged in negotiations to settle the disputes.

Successful Pfizer opposition against ‘Styriagra’ mark affirmed

3 May 2018 The EU General Court ruled in favour of Pfizer today after the company had opposed a trademark application made by Gall Pharma.

More on this story

TM oppositions against Pfizer suspended amid negotiations

19 April 2018 Two trademark oppositions against Pfizer have been suspended as the parties are engaged in negotiations to settle the disputes.

Successful Pfizer opposition against ‘Styriagra’ mark affirmed

3 May 2018 The EU General Court ruled in favour of Pfizer today after the company had opposed a trademark application made by Gall Pharma.

The doctrine of equivalents in the medtech arena

18 November 2020 The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.

More on this story

TM oppositions against Pfizer suspended amid negotiations

19 April 2018 Two trademark oppositions against Pfizer have been suspended as the parties are engaged in negotiations to settle the disputes.

Successful Pfizer opposition against ‘Styriagra’ mark affirmed

3 May 2018 The EU General Court ruled in favour of Pfizer today after the company had opposed a trademark application made by Gall Pharma.

The doctrine of equivalents in the medtech arena

18 November 2020 The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent